Hereditary forms of nephrolithiasis that cause marked excretion of insoluble minerals lead to recurring stones from childhood and risk for chronic kidney disease. Therefore, the Rare Kidney Stone Consortium (RKSC) was formed 5 years ago to advance the care of primary hyperoxaluria, cystinuria, Dent disease, and adenine phosphoribosyltransferase deficiency. Secure, web-based registries and tissue banks have been established and are open for collaborative projects. The RKSC provides readily available disease information, diagnostic testing, hypotheses for pilot studies, and well-characterized patient groups for clinical trials. Partnerships with patient advocacy groups (PAGs) for each of the diseases allows rapid spread of information among patients, families, and local physicians. Together with our PAGs we recently hosted successful patient and family education days in New York, London, and Rochester, MN. We have expanded training and research opportunities for young investigators, and successfully directed them to rare diseases research. The primary goal of this RKSC renewal is to expand our successful base.
Specific aims are: (1) Integrate and engage patients and PAGs as research partners of the RKSC to improve disease outcomes. (2) Identify patients at risk of progressive loss of kidney function. (3) Identify pathways of kidney injury. (4) Identify novel therapeutic targets for potential pilot studies. The RKSC will pursue these goals in 4 interlinked projects, each centered around a disease process. A key component will be secure web-based patient databases used to support tissue bank programs and appropriate clinical studies. We will leverage our successful registries to establish active follow-up of prospective cohorts in this funding cycle. Longitudinal data collection will further define the natural history, quality of life, and inflammatory biosignature f each disease. The RKSC success has been recognized with significant co-funding of our programs by our affiliated PAGs and institutions this cycle ($198,500 +/year).

Public Health Relevance

Ready availability of diagnostic testing, pooling of data from patient experience, availability of tissue banks open to all investigators and a consortium for cooperative exchange of information among investigators, clinicians, and patients, and sharing of resources among researchers, will improve care and outcomes for patients with rare stone diseases and advance the science.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel ()
Program Officer
Rasooly, Rebekah S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Nazzal, Lama; Puri, Sonika; Goldfarb, David S (2016) Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrol Dial Transplant 31:375-82
Kovacevic, Larisa; Lu, Hong; Caruso, Joseph A et al. (2016) Renal Tubular Dysfunction in Pediatric Urolithiasis: Proteomic Evidence. Urology 92:100-5
Runolfsdottir, Hrafnhildur Linnet; Palsson, Runolfur; Agustsdottir, Inger M et al. (2016) Kidney Disease in Adenine Phosphoribosyltransferase Deficiency. Am J Kidney Dis 67:431-8
Brooks, Ellen R; Hoppe, Bernd; Milliner, Dawn S et al. (2016) Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria. Am J Nephrol 43:293-303
Amin, Rasheda; Eid, Loai; Edvardsson, Vidar O et al. (2016) An unusual cause of pink diapers in an infant: Questions and Answers. Pediatr Nephrol 31:575, 577-80
Lieske, John C; Turner, Stephen T; Edeh, Samuel N et al. (2016) Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. J Nephrol 29:45-51
Whittamore, Jonathan M; Hatch, Marguerite (2016) The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man. Urolithiasis :
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Tang, Xiaojing; Brown, Matthew R; Cogal, Andrea G et al. (2016) Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients. Physiol Rep 4:
Zhao, Fang; Bergstralh, Eric J; Mehta, Ramila A et al. (2016) Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol 11:119-26

Showing the most recent 10 out of 62 publications